PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
出版年份 2019 全文链接
标题
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2019-03-20
DOI
10.1080/21645515.2019.1571892
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Atézolizumab (Tecentriq ® ) : activité, indication et modalités d’utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques
- (2018) Alice Bernard-Tessier et al. BULLETIN DU CANCER
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
- (2018) Zachary J. Brown et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
- (2018) Makoto Tahara et al. CANCER SCIENCE
- Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma
- (2018) Chun Jye Lim et al. GUT
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus
- (2018) Emine Kilic Bagir et al. JOURNAL OF CLINICAL PATHOLOGY
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Daniel Gallacher et al. PHARMACOECONOMICS
- Combining chemotherapy with PD-1 blockade in NSCLC
- (2018) Matthen Mathew et al. PHARMACOLOGY & THERAPEUTICS
- Personalized vaccines for cancer immunotherapy
- (2018) Ugur Sahin et al. SCIENCE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage
- (2018) Kuan Hu et al. Translational Oncology
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors
- (2018) Bobby Daly et al. JAMA Oncology
- Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1
- (2018) Ronit Mazor et al. CELLULAR IMMUNOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Human occupation of northern Australia by 65,000 years ago
- (2017) Chris Clarkson et al. NATURE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Atezolizumab Extends Survival for Breast Cancer
- (2017) Cancer Discovery
- CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells
- (2017) Meagan R. Rollins et al. Journal of Immunology Research
- Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
- (2017) Ester Simeone et al. OncoImmunology
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
- (2016) Chunwan Lu et al. OncoImmunology
- Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
- (2016) Gerald S. Falchook et al. Journal for ImmunoTherapy of Cancer
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sex equality can explain the unique social structure of hunter-gatherer bands
- (2015) M. Dyble et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
- (2015) Anne-Marit Sponaas et al. PLoS One
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- The PD-1/PD-Ls pathway and autoimmune diseases
- (2014) Suya Dai et al. CELLULAR IMMUNOLOGY
- Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
- (2014) Peiyuan Lu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
- (2013) Vamsidhar Velcheti et al. Journal of Thoracic Oncology
- Local Blockade of Epithelial PDL-1 in the Airways Enhances T Cell Function and Viral Clearance during Influenza Virus Infection
- (2013) Beth McNally et al. JOURNAL OF VIROLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
- (2012) Nikolaos Patsoukis et al. CELL CYCLE
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis
- (2010) Philippe O. Gannon et al. INTERNATIONAL JOURNAL OF CANCER
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started